Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery
to prolong life and provide cure. However, many of these treatments can cause …

Background Gastrointestinal perforation is a serious adverse event associated with
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …

Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …

Drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are a
rapidly growing chemotherapy class for treatment of solid tumors. This targeted therapy is …

Recognition and management of treatment-related cardiovascular toxicity, defined as either
an acute cardiac event or a chronic condition, has been tightly integrated into routine cancer …

Purpose Gastrointestinal injury occurs rarely with agents that affect the vascular endothelial
growth factor receptor and with abdominal stereotactic body radiation therapy (SBRT). We …

Combining the latest targeted biologic agents with the most advanced radiation
technologies has been an exciting development in the treatment of cancer patients …

Vascular toxicity is a frequent adverse effect of current anticancer chemotherapies and often
results from endothelial dysfunction. Vascular endothelial growth factor inhibitors (VEGFi) …

Anti-VEGF (vascular endothelial growth factor) therapy with the monoclonal antibody
bevacizumab can cause gastrointestinal (GI) perforations. In recent years it became …

Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment
of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of …